Reply to comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”

Abstract

We read with interest Arshad et al.’s thoughts on our guidance, which was made available to and revised in response to feedback from clinicians from the outset of the COVID-19 pandemic. We note that the authors have not commented on any specific aspect of the article’s content; instead proffering their appraisal of the authors, coupled with a call for business as usual alongside an inference that amidst an unprecedented pivot in NHS care towards patients with COVID-19 at a time when up to a fifth of medical staff were off work, such guidance was redundant. The in-excess of 2200 downloads of, and over 400 visits to, the treatment protocols and webpages respectively associated with this guidance suggest such conjecture to be erroneous, but we fully dissect their multiple assumptions in turn here.

Rights

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Cite as

Downloadable citations

Identifiers

DOI

https://doi.org/10.1038/s41416-020-01133-8

Repository URI

https://eprints.gla.ac.uk/291204/